Therapeutics News

Harrow announced that it signed agreements with Santen Pharmaceutical Co. affiliates to acquire their branded ophthalmic portfolio and also with Novaliq GmbH to acquire Vevye.

NEW ORLEANS — In this Healio Video Perspective from the ARVO meeting, Mark A. Bullimore, MCOptom, PhD, FAAO, discussed the use of atropine for myopia control in the LAMP study.

Eye care pharmaceutical company Harrow announced the launch of its next-generation compounded atropine formulations, which are now available at ImprimisRx, its compounding and mail-order pharmacy subsidiary.

The FDA has accepted a new drug application for reproxalap, an investigational new drug candidate for signs and symptoms of dry eye disease, manufacturer Aldeyra Therapeutics announced in a press release.

Switching to preservative-free topical formulations for glaucoma may improve patient adherence to treatment and improve symptoms and signs of ocular surface disease, according to a study published in Clinical Ophthalmology.

SAN DIEGO — Results from a pilot study showed that low-dose doxycycline may hold promise as an adjunct treatment for IOP reduction, according to a poster presented at Academy 2022.

SAN DIEGO — Patients with stage 1 neurotrophic keratitis experienced significant improvements in corneal sensitivity and best-corrected visual acuity after an 8-week course of Oxervate, according to a study presented at Academy 2022.

SAN DIEGO — Phentolamine with and without low-dose pilocarpine significantly improved distance-corrected near visual acuity without compromising distance vision, according to a poster presented at Academy 2022.

SAN DIEGO — Oral drug candidate APX3330 showed a “favorable safety and tolerability profile” in patients with diabetes and diabetic retinopathy, according to research presented in a poster at Academy 2022.

MILAN — Caring for patients in conflict zones, Ukrainian ophthalmologists work under constant pressure and face multiple challenges.